Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation

Abstract excerpt

Advanced human thyroid cancers, particularly those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf murine sarcoma viral oncogene homolog B1) mutations. However, the degree to which these cancers are dependent on BRAF expression is still unclear. To address this question, we generated mice expressing one of the most commonly detected BRAF mutations in human papillary...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Melanoma and MAPK Pathways
• Share to S100 Proteins and Annexins
• Share to Thyroid Cancer Diagnosis and Treatment